Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on September 12, 2016. The filing reports a scientific presentation event rather than financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event under Item 8.01.
Material Changes
There are no financial material changes reported in this document. The significant event is the presentation of a poster titled "Therapeutic Efficacy of NSI-189 in Diabetic Mice" by Dr. Karl Johe, Ph.D., Chief Scientific Officer, at the Annual Meeting of the Diabetic Neuropathy Study Group of the EASD in Bucharest, Romania.
Outlook and Management Commentary
Management commentary is limited to the announcement of the scientific presentation. No financial guidance, risk factors, or contingencies are disclosed in this specific filing.
Investor Verification Checklist
- Verify the full text of the attached press release (Exhibit 99.01) for detailed data on the NSI-189 study.
- Confirm the company name is Neuralstem, Inc., as the metadata reference to Palisade Bio, Inc. appears to be an error.
- Review subsequent filings for financial performance, as this 8-K contains no financial statements.